Patents by Inventor Rob Falconer

Rob Falconer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds containing a vascular disrupting agent
    Patent number: 10556014
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 11, 2020
    Assignee: ELLIPSES PHARMA LIMITED
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
    Publication number: 20180228910
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: March 16, 2018
    Publication date: August 16, 2018
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Compounds containing a vascular disrupting agent
    Patent number: 9956296
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 1, 2018
    Assignee: INCANTHERA LTD
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
    Publication number: 20160243252
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: May 6, 2016
    Publication date: August 25, 2016
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Compounds containing a vascular disrupting agent
    Patent number: 9358303
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 7, 2016
    Assignee: Incanthera Ltd
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Compounds
    Publication number: 20140179592
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 26, 2014
    Applicant: INCANTHERA LIMITED
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Lawrence Patterson, Jennifer Atkinson, Michael Bibby
  • Compounds containing a vascular disrupting agent
    Patent number: 8691751
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: April 8, 2014
    Assignee: Incanthera Ltd
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Atkinson, Mike Bibby
  • GROWTH FACTOR
    Publication number: 20100168036
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: March 27, 2008
    Publication date: July 1, 2010
    Applicant: University of Bradford
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Atkinson, Mike Bibby